1111637-94-5

Basic information

• Product Name: 5-Bromo-3-methyl-7-azaindole
• Synonyms: 5-Bromo-3-methyl-7-azaindole;5-Bromo-3-methyl-1H-pyrrolo[2,3-b]pyridine;5-BroMo-3-Methyl-7-azaind...;1H-Pyrrolo[2,3-b]pyridine, 5-broMo-3-Methyl-;5-bromo-3-methyl-pyrrolo[2,3-b]pyridine
• CAS NO: 1111637-94-5
• Molecular Formula: C₈H₇BrN₂
• Molecular Weight: 211.05858
• Mol File: 1111637-94-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 1.654±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 13.22±0.40(Predicted)
• CAS DataBase Reference: 5-Bromo-3-methyl-7-azaindole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Bromo-3-methyl-7-azaindole(1111637-94-5)
• EPA Substance Registry System: 5-Bromo-3-methyl-7-azaindole(1111637-94-5)

Safety Data

• Hazardous Substances Data: 1111637-94-5(Hazardous Substances Data)

Usage

General Description

5-Bromo-3-methyl-7-azaindole is a chemical compound with the molecular formula C9H8BrN3. It is a heterocyclic compound containing a five-membered nitrogen-containing ring with a bromine atom and a methyl group attached at specific positions. 5-Bromo-3-methyl-7-azaindole is used in pharmaceutical and organic synthesis applications due to its potential as a building block for the preparation of various biologically active molecules and pharmaceuticals. It has also been studied for its potential anticancer and anti-inflammatory properties. Additionally, 5-Bromo-3-methyl-7-azaindole has been used as a precursor in the synthesis of other heterocyclic compounds and is a valuable research tool in the field of organic chemistry.

Upstream product

• 77992-44-0 5-bromo-2-hydrazinylpyridine 
• 1111637-93-4 5-bromo-3-methyl-2-(trimethylsilyl)-1H-pyrrolo[2,3-b]pyridine 
• 98545-74-5 allyl-(3,5-dibromo-pyridin-2-yl)-amine 
• 35486-42-1 2-amino-3,5-dibromopyridine 
• 757978-18-0 3-iodo-5-bromo-1H-pyrrolo[2,3-b]-pyridine 
• 1620574-95-9 5-bromo-3-methyl-1-tosyl-1H-pyrrolo[2,3-b]pyridine 
• 1620574-94-8 5-bromo-3-(chloromethyl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine 
• 1620574-93-7 (5-bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)methanol 
• 1207626-51-4 5-bromo-1-tosyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde 
• 875639-15-9 5-bromo-3-iodo-1-(4-methylbenzene-1-sulfonyl)-1H-pyrrolo[2,3-b]pyridine 

Downstream Products

• 1111637-95-6 3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrolo[2,3-b]pyridine 
• 1111637-97-8 5-bromo-3-methyl-1-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine 
• 916258-24-7 tert-butyl 5-bromo-3-methyl-1H-pyrazolo[3,4-b]pyridine-1-carboxylate 

Relevant articles and documents

2'-(QUINOLIN-3-YL)-5',6'-DIHYDROSPIRO[AZETIDINE-3,4'-PYRROLO[1,2-B]PYRAZOLE]-1-CARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS AS MAP4K1 (HPK1) INHIBITORS FOR THE TREATMENT OF CANCER

The present invention relates to Map4K1 inhibitors of formula (I), to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients. The present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control.

TRICYCLIC DLK INHIBITORS AND USES THEREOF

The invention relates to compounds of formula (I) and salts thereof, wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.

PYRAZOLE COMPOUNDS

The present invention is directed to compounds of Formula (I) and to pharmaceutically acceptable salts thereof, their synthesis, and their use as Raf inhibitors.